Pérez-Miralles Francisco, Prefasi Daniel, García-Merino Antonio, Ara José Ramón, Izquierdo Guillermo, Meca-Lallana Virginia, Gascón-Giménez Francisco, Martínez-Ginés María Luisa, Ramió-Torrentà Lluis, Costa-Frossard Lucienne, Fernández Óscar, Moreno-García Sara, Medrano Nicolás, Maurino Jorge, Casanova Bonaventura
Neuroimmunology Unit, Neurology Department, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell, 106, 46026 Valencia, Spain.
Medical Department, Roche Farma S.A., Calle de la Ribera del Loira, 50, 28042 Madrid, Spain.
Mult Scler Relat Disord. 2021 May;50:102860. doi: 10.1016/j.msard.2021.102860. Epub 2021 Feb 23.
BACKGROUND: Primary progressive multiple sclerosis (PPMS) has long been defined by progressive disability accrual in the absence of initial relapses. However, its underlying neurodegenerative process seems to be accompanied by central nervous system inflammation. A new classification defined multiple sclerosis courses according to clinical/radiological activity and progression. We provide further insight into PPMS activity according to this classification and other daily living aspects. METHODS: This was a multicentre, prospective, cohort study including 55 adult patients with PPMS according to 2010 McDonald criteria, within ten years from neurologic symptom onset and not receiving disease-modifying therapies during the past six months, who were followed up for 12 months. The primary study endpoint was the percentage of patients with active disease based on clinical relapses and/or magnetic resonance activity. Disability progression, cognitive function, physical/psychological impact, depression symptoms, stigma and employment were secondary endpoints. RESULTS: Eleven (25.6%) patients exhibited multiple sclerosis activity throughout the 12-month study follow-up. Fourteen showed non-active multiple sclerosis without progression, 11 non-active multiple sclerosis with progression, 6 active multiple sclerosis without progression and 4 active multiple sclerosis with progression; one patient with disease activity was not assessable for progression. Cognitive function scores remained unchanged or increased, disease physical impact was maintained and disease psychological impact significantly decreased. The proportion of patients with depression symptoms or stigma remained without significant changes as well as employment outcomes. CONCLUSION: This study shows that one-fourth of PPMS patients may exhibit disease activity over one year, with disability progression in approximately one-third but without worsening of cognitive function, disease impact, depression, stigma or employment outcomes.
背景:原发性进行性多发性硬化症(PPMS)长期以来被定义为在无初始复发情况下逐渐累积残疾。然而,其潜在的神经退行性过程似乎伴有中枢神经系统炎症。一种新的分类方法根据临床/放射学活动和进展对多发性硬化症病程进行了定义。我们根据这种分类以及其他日常生活方面,进一步深入了解PPMS的活动情况。 方法:这是一项多中心、前瞻性队列研究,纳入了55例符合2010年麦克唐纳标准的成年PPMS患者,这些患者在出现神经症状后的十年内,且在过去六个月未接受疾病修饰治疗,随访12个月。主要研究终点是基于临床复发和/或磁共振活动的疾病活动患者百分比。残疾进展、认知功能、身体/心理影响、抑郁症状、污名化和就业情况为次要终点。 结果:在为期12个月的研究随访中,11例(25.6%)患者表现出多发性硬化症活动。14例显示无进展的非活动性多发性硬化症,11例无进展的非活动性多发性硬化症伴进展,6例有进展的活动性多发性硬化症无进展,4例有进展的活动性多发性硬化症伴进展;1例有疾病活动的患者无法评估进展情况。认知功能评分保持不变或升高,疾病对身体的影响维持不变,疾病对心理的影响显著降低。有抑郁症状或污名化的患者比例以及就业结果均无显著变化。 结论:本研究表明,四分之一的PPMS患者可能在一年内表现出疾病活动,约三分之一的患者有残疾进展,但认知功能、疾病影响、抑郁、污名化或就业结果并无恶化。